CSL has pulled studies or trials on three therapies and says US regulators have raised manufacturing concerns about a key new treatment in rare late-stage setbacks for the biotechnology giant’s ...

Genevant LNP technology will provide a vehicle for Editas’ CRISPR/Cas12a gene therapy. Credit: ART-ur / Shutterstock. Editas Medicine and Genevant Sciences will collaborate to develop gene editing ...

Russo and Hay, of New Zealand, are interested in building on CGRP action with a potential novel therapy. It turns out CGRP doesn’t hit just one receptor on the surface of cells, like a key that ...